Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD5 | P21918 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29324960 | 0.81 | HTR2C (0.42) | SIGMAR1NOTUMNPSR1 | |
| SCHEMBL29325214 | 0.78 | GID4 (0.41) | GID4DRD2DRD1DRD4DRD5 | |
| SCHEMBL29325210 | 0.78 | GID4 (0.41) | GID4 | |
| SCHEMBL30004585 | 0.78 | GID4 (0.41) | GID4DRD2DRD1DRD4DRD5 | |
| SCHEMBL7919900 | 0.78 | GID4 (0.41) | GID4DRD2DRD1DRD4DRD5 | |
| SCHEMBL29325486 | 0.78 | GID4 (0.41) | GID4DRD2DRD1DRD4DRD5 | |
| SCHEMBL29325347 | 0.78 | GID4 (0.41) | GID4 | |
| SCHEMBL24539163 | 0.75 | ADRA2A (0.47) | GID4DRD2DRD1DRD5SIGMAR1 | |
| SCHEMBL10557242 | 0.75 | FFAR1 (0.35) | DRD2SIGMAR1NOTUMHTR1ALMNA | |
| SCHEMBL10226366 | 0.73 | SIGMAR1 (0.54) | DRD2DRD4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | GID4 677/4885DRD2 4649/4885DRD1 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.